ABC-CT (Autism Biomarkers Consortium for Clinical Trials)
To see if eye tracking (ET) or electroencephalogram (EEG) assessments have potential use in future clinical trials of Autism Spectrum Disorders (ASD).
To see if eye tracking (ET) or electroencephalogram (EEG) assessments have potential use in future clinical trials of Autism Spectrum Disorders (ASD).
Individuals with Down syndrome are at risk for the development of Alzheimer's disease. This study seeks to explore if neurodegenerative biomarkers of this condition are present in childhood. In addition, this study will explore the possibility of these same biomarkers being present in children with autism spectrum disorder and other neurodevelopmental conditions.
The goal of this study is to help researchers across the nation develop and tailor healthcare treatments to the individual. They will do this by collecting data & biospecimens that may enable a broad spectrum of research studies.
This prospective, longitudinal study aims to measure and describe the amount and frequency of physical activity, feeding, and sleeping across days and months in infancy.
Learn more about healthy baby development and develop new tools for pediatricians so they can better support the unique development of each child.
We want to learn more about how cancer treatment, such as immunotherapy (i.e., CAR T cell treatment), affects the brain, learning, and behavior in patients with Acute Lymphoblastic Leukemia (ALL).
This study uses sensitive measures of brain blood flow an its response to change to inhaled oxygen levels to determine how the brain protects its oxygen supply.
To determine the extent that subtle brain injury, blood flow to the brain, and learning problems relate to type of brain tumor treatment given.
We are studying how responses to the rotavirus vaccine are influenced by infant nutrition and other exposures in different areas of the world. The information we get from this study may help us to understand how to best protect infants from rotavirus and other infections.
To evaluate long-term safety of Humira in pediatric patients (between the ages of 6 and 17 years inclusive at the time of enrollment) with moderately to severely active CD who are prescribed and treated in accordance with the approved local Humira product label under the conditions of routine clinical setting.